Arcus will now refocus its efforts outside of TIGIT, specifically on its asset casdatifan, an HIF-2a inhibitor once backed by Gilead, as well as its earlier stage small-molecule inflammatory and ...

Kite, a Gilead Sciences company, recently reported new analysis showing that its CAR T therapy Yescarta delivers consistent ...

A study using TIGIT and PD-1 drugs for gastrointestinal disease was canceled for “futility” at an early checkpoint, another ...

Arcus Biosciences and Gilead Sciences are discontinuing a Phase 3 trial of an experimental cancer treatment after an interim review showed the therapy was unlikely to help patients live longer.

Arcus Biosciences (RCUS) fell ~14% in the premarket on Friday after the company announced the discontinuation of a Phase 3 ...

Arcus ends its Phase 3 STAR-221 trial after a futility review and shifts R&D toward casdatifan, supported by strong early RCC ...

Gilead and Arcellx reported promising data for their CAR-T therapy anito-cel at the annual American Society of Hematology ...

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best pharma stocks to invest in. Cantor Fitzgerald analyst Carter Gould ...

Biopharmaceutical company Gilead Sciences has hired Bob Allen as head of omnichannel strategy and digital transformation for public affairs.

Gilead Sciences' Kite unit has showcased three new CAR-T therapies at ASH, headed by multiple myeloma candidate ...

Perettie’s confidence stems from data shared at ASH on Dec. 6, when Kite revealed that patients treated with the Arcellx-partnered autologous therapy achieved a 96% overall response rate at the 15.9 ...

After a yearslong court battle against a network of alleged HIV drug fraudsters, Gilead Sciences has emerged victorious with $175.2 million in judgments. Gilead has traveled a long road since the ...